Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M404318200 on May 19, 2004

J. Biol. Chem., Vol. 279, Issue 34, 35139-35149, August 20, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/34/35139    most recent
M404318200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kepley, C. L.
Right arrow Articles by Saxon, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kepley, C. L.
Right arrow Articles by Saxon, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Co-aggregation of Fc{gamma}RII with Fc{epsilon}RI on Human Mast Cells Inhibits Antigen-induced Secretion and Involves SHIP-Grb2-Dok Complexes*

Christopher L. Kepley{ddagger}§, Sharven Taghavi{ddagger}, Graham Mackay¶, Daocheng Zhu||, Penelope A. Morel**, Ke Zhang||, John J. Ryan{ddagger}{ddagger}, Leslie S. Satin§§, Min Zhang§§, Pier P. Pandolfi¶¶, and Andrew Saxon||

From the Departments of {ddagger}Internal Medicine, {ddagger}{ddagger}Biology, and §§Pharmacology and Toxicology, Virginia Commonwealth University Health Systems, Richmond, Virginia 23298, the Department of Pharmacology, University of Melbourne, Melbourne, Australia 3010, the **Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, the ¶¶Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and the ||Department of Medicine, University of California, Los Angeles, California 90033

Received for publication, April 19, 2004


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Signaling through the high affinity IgE receptor Fc{epsilon}RI on human basophils and rodent mast cells is decreased by co-aggregating these receptors to the low affinity IgG receptor Fc{gamma}RII. We used a recently described fusion protein, GE2, which is composed of key portions of the human {gamma}1 and the human {epsilon} heavy chains, to dissect the mechanisms that lead to human mast cell and basophil inhibition through co-aggregation of Fc{gamma}RII and Fc{epsilon}RI. Unstimulated human mast cells derived from umbilical cord blood express the immunoreceptor tyrosine-based inhibitory motif-containing receptor Fc{gamma}RII but not Fc{gamma}RI or Fc{gamma}RIII. Interaction of the mast cells with GE2 alone did not cause degranulation. Co-aggregating Fc{epsilon}RI and Fc{gamma}RII with GE2 1) significantly inhibited IgE-mediated histamine release, cytokine production, and Ca2+ mobilization, 2) reduced the antigen-induced morphological changes associated with mast cell degranulation, 3) reduced the tyrosine phosphorylation of several cellular substrates, and 4) increased the tyrosine phosphorylation of the adapter protein downstream of kinase 1 (p62dok; Dok), growth factor receptor-bound protein 2 (Grb2), and SH2 domain containing inositol 5-phosphatase (SHIP). Tyrosine phosphorylation of Dok was associated with increased binding to Grb2. Surprisingly, in non-stimulated cells, there were complexes of phosphorylated SHIP-Grb2-Dok that were lost upon IgE receptor activation but retained under conditions of Fc{epsilon}-Fc{gamma} co-aggregation. Finally, studies using mast cells from Dok-1 knock-out mice showed that IgE alone triggers degranulation supporting an inhibitory role for Dok degranulation. Our results demonstrate how human Fc{epsilon}RI-mediated responses can be inhibited by co-aggregation with Fc{gamma}RIIB and implicate Dok, SHIP, and Grb2 as key intermediates in regulating antigen-induced mediator release.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Mast cells generate pro-inflammatory mediators that initiate and propagate allergic inflammation. IgE-mediated mediator release is initiated through the high affinity IgE receptor Fc{epsilon}RI,1 in which the {alpha} subunit has IgE binding activity and the {beta} and {gamma} subunits have signaling activity. Signaling is primarily mediated by immunoreceptor tyrosine-based activation motifs (ITAMs) located in the carboxyl-terminal cytoplasmic tails of each of the {beta} and {gamma} subunits. ITAMs are typically 26- or 27-amino acid stretches including two YXXL motifs separated by 9 or 10 amino acids. Cross-linking IgE-primed receptors with a multivalent antigen results in the activation of Lyn, which in turn phosphorylates ITAMs, creating docking sites for Syk kinase family members and permitting signal propagation (for review, see Ref. 1).

Many immune cells that express ITAM-containing antigen receptors also express receptors with a related immunoreceptor tyrosine-based inhibitory motifs (ITIMs). ITIMs are 13-amino acid sequences containing a single YXXL motif (2). They were first recognized in the cytoplasmic tails of the Fc{gamma}RIIB isoform (Fc{gamma}RIIB1) of rodent B cells. Their negative signaling activity was revealed by studies showing that co-aggregating the BCR with Fc{gamma}RIIB1 inhibits the BCR-mediated activation of rodent B cells (3). Studies in murine bone marrow derived mast cells (BMMCs) showed that co-aggregating murine Fc{gamma}RIIB to Fc{epsilon}RI also inhibits IgE-induced mast cell degranulation and that this inhibition is dependent on the intact intracytoplasmic tail of the Fc{gamma}RIIB (4). Further studies using RBL-2H3 cells transfected with cDNA encoding human wild type and mutant Fc{gamma}RIIB showed that the intracytoplasmic domain responsible for the negative signaling is the ITIM found in Fc{gamma}RIIB (5). Subsequently, it was shown that the phosphorylation of the mast cell Fc{gamma}RIIB-ITIM is mediated by Lyn and results in the recruitment of specific tyrosine phosphatases (6).

The negative regulation of signaling through ITAM-containing receptors by signals generated by the co-cross-linked ITIM-containing Fc{gamma}RIIB isoforms has been demonstrated in mouse and human B cells that naturally co-express the BCR and Fc{gamma}RIIB1, in T cell and rodent mast cell lines that express the T cell receptor or Fc{epsilon}RI plus endogenous or transfected Fc{gamma}RIIB1 (5), and in human basophils (7). Negative regulation by other ITIM-containing receptors has been demonstrated in several other model systems (8). It is not clear whether human mast cells express ITIM receptors and whether IgE-mediated responses can be down-regulated through their activity. Although there has been a great effort to discover and study ITIM receptors, little progress has been made in harnessing their inherent inhibitory properties for potential therapeutic interventions.

We recently showed that a novel human Fc{epsilon}-Fc{gamma} receptor-binding fusion protein (GE2) could inhibit human basophil functional and biochemical responses in vitro and in vivo (9, 64). Subsequently, it has been demonstrated that GE2 can inhibit IgE production by human B cell (10) and cytokine production from Fc{epsilon}RI/Fc{gamma}RII-expressing, Langerhan cell-like dendritic cells (11).

Here we used umbilical cord blood-derived human mast cells (CBMCs) to test the mechanisms of inhibition by Fc{epsilon}RI-Fc{gamma}RII co-aggregation on human mast cells. We demonstrated that human mast cells express Fc{gamma}RII (CD32) but not Fc{gamma}RI (CD64) or Fc{gamma}RIII (CD16). We provide the first evidence that the functional responses of human mast cell Fc{epsilon}RI can be down-regulated by Fc{gamma}RII. The inhibition involves alterations in protein tyrosine phosphorylation, including Syk. We provide evidence that Grb2, Dok, and SHIP phosphorylation is associated with mast cell inactivation and Fc{gamma}RII-mediated inhibition of Fc{epsilon}RI responses. Although previous rodent studies have implicated SHIP, our findings further implicate Grb2 and Dok as additional "gatekeepers" of human Fc{epsilon}RI signaling.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Antibodies and Reagents—Anti-Fc{epsilon}RI {alpha} subunit mAb 22E7 (IgG1; Ref. 12) was a gift from Dr. J. Kochan. Monoclonal antiphosphotyrosine (Tyr(P); IgG1), anti-Grb2 (rabbit polyclonal), and anti-RasGAP (rabbit polyclonal) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Nonspecific mouse IgG1 (MOPC31C), anti-Fc{gamma}RIII (CD16), anti-actin, anti-4-hydroxy-3-nitrophenacetyl (NP) IgE (mouse), and CD22 mAbs (IgG1) were from Sigma. The anti-Fc{gamma}RII AT10 mAbs (IgG1; recognizing all Fc{gamma}RII isoforms) and anti-Fc{gamma}RI (anti-CD64; clone 32.2, IgG1) Abs were obtained from Medarex (Annendale, NJ). The chimeric human anti-NIP IgE Abs were from Serotec Ltd. (Oxford, UK). The mAb against signal-regulatory protein-{alpha} (SIRP-{alpha}) (IgG1) was obtained from Alexis Biochemicals. The anti-Syk Ab (IgG2a) was obtained from Upstate (Waltham, MA). The anti-c-kit (IgG1) and CD81 (IgG1) were from Immunotech (Marseille, France). The mAb anti-CD72 (IgG1) was from Pharmingen. The Ab detecting mast cell-associated antigen (G63; IgG1; MAFA) was a gift from Enrique Ortega, Mexico City, Mexico. Abs recognizing p62dok (Dok) were a gift from Dr. John Cambier, National Jewish Hospital, Denver, CO. The human Fc{gamma}-Fc{epsilon} Ig chimeric fusion protein (GE2) was produced as described previously (9). All IgE preparations were routinely centrifuged at 60,000 x g to remove aggregates.

Umbilical CBMCs—Umbilical cord blood was collected from normal, full-term deliveries as approved by the Human Studies Committees at the Medical College of Virginia. EDTA-treated (0.01% final) cord blood was layered over Ficoll-Hypaque (density 1.077; Sigma) 1:1 (v/v), and the tubes were centrifuged at 350 x g for 20 min at room temperature with no brake. Mononuclear cells recovered at the interphase were washed with phosphate-buffered saline with 0.1% bovine serum albumin (PBS/BSA). If red blood cell contamination was present, the pellet was resuspended in PBS/BSA and was relayered over the Ficoll (1:1, v/v), centrifuged, and washed as above. The CD34+ stem cells were isolated using a negative selection mixture and magnetic separation of non-CD34-positive cells using the technique given by the manufacturer (Miltenyi, Auburn, CA). The cells were suspended at a concentration of ~0.5–1.0 x 106 cells/ml in Iscove's modified Dulbecco's medium (Sigma) supplemented with 10% fetal calf serum (Hyclone, Logan, UT), 100 ng/ml recombinant human stem cell factor and 50 ng/ml recombinant human interleukin-6 (IL-6) (both from BIOSOURCE, Camarillo, CA), 10 µM Hepes, 50 µM 2-mercaptoethanol, 4 mM L-glutamine, 1x minimum Eagle's medium amino acids, 1x vitamin solution (Invitrogen), 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 µg/ml streptomycin (13). To enhance Fc{epsilon}RI expression, human anti-NIP IgE (1 µg/ml) was added at least 1 week prior to each experiment (13). Cultures were maintained at 5% CO2 and 37 °C, and the medium was changed every 4–5 days with the cells placed back into the original flask. Cells were used at 6–9 weeks. As reported previously using a similar protocol (13), the purity of the mast cells was always greater than 90% as determined by tryptase immunostaining (14) (data not shown). Aliquots of cells were removed on different days and before use for the analysis of viability (by trypan blue exclusion) and for cytospin preparation.

Flow Cytometry—Cells were recovered by centrifugation at 800 x g at 4 °C, washed with PBS/BSA, and incubated for 30 min at 4 °C with a 1:500 dilution of normal human serum. The cells were washed and incubated with the indicated Abs (10 µg/ml) for 1 h at 4 °C. After antibody labeling, the cells were washed and incubated with a 1:100 dilution of F(ab')2-fluorescein isothiocyanate-goat anti-mouse for 30 min at 4 °C. After three washes, cells were resuspended in 400 µl of PBS/BSA. The mean intensity fluorescence was determined for at least 10,000 cells using a Coulter Epics Elite flow cytometer. MOPC31C nonspecific mouse IgG or non-immune rabbit IgG was used as a negative control. All experiments were performed in duplicate.

Cell Activation—CBMCs were suspended in fresh medium (without cytokines) and sensitized with 10 µg/ml human anti-NIP IgE overnight at 37 °C in a 5% CO2 incubator. The next morning, GE2 was added for at least 2 h to a final concentration indicated in the "Results" section. Cells were washed and activated, and mediator release was measured as described previously (15).

Intracellular Ca2+ Concentration ([Ca2+]i) Measurements—IgE-sensitized mast cells (1 x 105 cells/condition), with or without GE2 challenge, were loaded with 2 µM (final v/v) Indo-1 (Fig. 3A) or Fura-2/AM (Fig. 3B) for 30 min at room temperature on a rocking platform. Washed cells were resuspended in fresh HBSS and kept at 37 °C. Following acquisition of base-line fluorescence values for ~20–30 s using a FAC-Scaliber flow cytometer (Fig. 3A) or laser scanning confocal microscope system Olympus FluoView (Fig. 3B), HBSS with or without NIP/BSA or thapsigargin (Calbiochem) was added, and changes in the fluorescent ratio were measured for up to 10 min at 2-s intervals. Each experiment was done in duplicate.



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 3.
A, Fc{gamma}RII-Fc{epsilon}RI co-aggregation inhibits Fc{epsilon}RI-mediated Ca2+ mobilization in CBMCs. Cells were sensitized with 10 µg/ml of anti-NIP IgE with or without GE2, loaded with Indo-1, and challenged with 200 ng/ml NIP/BSA for 4 min. Change in absorbance was monitored using FACS analysis as described under "Experimental Procedures." Each plot represents the Ca2+ response of whole cell populations. The data are representative of two separate experiments. B, GE2 inhibits the release of intracellular calcium stores. Fura-2/AM-loaded cells were challenged with thapsigargin (thaps) with or without preincubation with GE2 (10 µg/ml). Change in absorbance was monitored as described under "Experimental Procedures." XL, cross-linker.

 
Transmission Electron Microscopy—Suspensions of IgE-sensitized CBMCs were challenged with or without GE2 (10 µg/ml) as above, washed, and incubated at 37 °C in prewarmed HBSS+ (HBSS with 1 mM CaCl2 and 1 mM MgCl2) without or with NIP/BSA (200 ng/ml) for 30 min. Cells were collected by centrifugation, and pellets were fixed in 2% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, for 30 min at room temperature, rinsed with cacodylate, and processed as described previously (16). Thin sections were observed using a Hitachi 600 transmission electron microscope.

Lysis, Immunoprecipitation, and Immunoblotting—IgE-sensitized mast cells, with or without GE2, were activated as above. Preparation of cell lysates, immunoprecipitation, and Western blotting were performed as described previously (7).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Identification of Fc{gamma}Rs on CBMCs—ITIM-containing receptors are an expanding family of immune inhibitory receptors that have the ability to inhibit immune responses (8). We are not aware of studies examining their expression on human mast cells. As seen in Fig. 1, CBMCs express, in addition to Fc{gamma}RIIB, the ITIM-containing receptor CD22 and the ITIM-like-containing receptor CD81.



View larger version (37K):
[in this window]
[in a new window]
  		FIG. 1.
ITIM receptor expression on CBMCs. Mast cells were incubated at 4 °C with Abs raised against a number of cell surface receptors discussed below (10 µg/ml) followed by fluorescein isothiocyanate-labeled goat anti-mouse IgG antibodies. An irrelevant mouse IgG (MOPC) was substituted for the receptor Abs as a negative control. mAbs 22E7, which binds the Fc{epsilon}RI {alpha} chain, and YB5B8, which binds c-kit, were positive controls. Positive expression was evident for CD22, CD32, and CD81. MAFA, mast cell function-associated antigen; SIRP-{alpha}, signal-regulatory protein-{alpha}. Inset, CBMCs express Fc{gamma}RIIB and not Fc{gamma}RIIA. Lysates of CBMCs (lane 3) were probed on two separate blots with the Fc{gamma}RIIA-specific (Ab260) or Fc{gamma}RIIB-specific (Ab163.96) Abs. As controls, Raji (lane 1, Fc{gamma}RIIB-positive, Fc{gamma}RIIA-negative) or U937 (lane 2, Fc{gamma}RIIB-negative, Fc{gamma}RIIA-positive) cell lines were examined in parallel (20). The molecular mass marker is indicated in kilodaltons.

 
Similar to what we have shown previously for human basophil Fc{gamma}Rs, human mast cells exclusively express the low affinity IgG receptor Fc{gamma}RII. Thus CBMCs react strongly with the pan-anti-Fc{gamma}RII mAb AT10 (Fig. 1). Confirming earlier studies examining cultured human mast cells, little or no Fc{gamma}RI or Fc{gamma}RIII expression was detected (17). Thus, cultured human mast cells express only the low affinity IgG receptor Fc{gamma}RII. There are multiple Fc{gamma}RII isoforms, representing the products of three distinct genes (18). Results of reverse transcription-PCR analysis using previously described methods (7, 19) showed that CBMCs contain transcripts for the ITIM-containing Fc{gamma}RII isoform Fc{gamma}RIIB and the ITAM-containing Fc{gamma}RII isoforms Fc{gamma}RIIA and Fc{gamma}RIIC (data not shown). However, we did not detect surface expression of Fc{gamma}RIIA by FACS analysis using the Fc{gamma}RIIA-specific Ab IV.3 (data not shown). In addition, no Fc{gamma}RIIA was detected by Western blot analysis in mast cell lysates using an Ab raised against the cytoplasmic tail of Fc{gamma}RIIA (Ab260), whereas strong signals were detected when using an Fc{gamma}RIIB-specific Ab (Ab163; a gift of Dr. Susheela Tridandapani, Ohio State University, Columbus, OH) (Fig. 1, inset) (20). Thus, although CBMCs express mRNA for Fc{gamma}RIIA, it appears that only Fc{gamma}RIIB is expressed on the cellular membrane in unstimulated, human CBMCs.

Fc{gamma}RII-Fc{epsilon}RI Co-aggregation Inhibits Fc{gamma}RI-dependent Human Mast Cell Degranulation—Previous investigators have established that Fc{gamma}RII-Fc{epsilon}RI co-aggregation can inhibit Fc{epsilon}RI responses in a variety of model systems. We designed and described an Fc{gamma}R-Fc{epsilon}R-binding chimeric protein that can directly induce this interaction (GE2; Ref. 9). Fig. 2A shows the secretory responses induced by adding optimal concentrations of NIP/BSA (200 ng/ml) to CBMCs that had been sensitized with human anti-NIP IgE and treated with the GE2 fusion protein. GE2 incubation for 2 h prior to antigen stimulation inhibited IgE-mediated histamine release in a dose-dependent fashion. This inhibition could not be accounted for by competition between IgE and GE2 for Fc{epsilon}RI binding as substitution of nonspecific purified IgE myeloma protein (PS-IgE) for the GE2 resulted in IgE-mediated release comparable with non-GE2-challenged control cells. Similar to what we reported previously using human basophils (9), no secretion is induced by adding chimeric protein alone to IgE-sensitized and unsensitized cells (data not shown). In four separate experiments, co-aggregating Fc{epsilon}RI and Fc{gamma}RII with GE2 (10 µg/ml) reduced Fc{epsilon}RI-mediated histamine secretion by an average of 68%.



View larger version (42K):
[in this window]
[in a new window]
  		FIG. 2.
Fc{gamma}RII-Fc{epsilon}RI co-aggregation inhibits Fc{epsilon}RI-mediated mast cell degranulation and TNF-{alpha} production. CBMCs were incubated with anti-NIP IgE (10 µg/ml) with or without a 2-h incubation with GE2 or nonspecific IgE (PS) in Iscove's medium at 37 °C in a 5% CO2 incubator. The cells were washed and incubated with or without 200 ng/ml NIP/BSA or anti-IgE for 45 min (histamine release) or 12 h (cytokine production), and mediator release was measured in the supernatants. Results are represented as the mean ± S.E. of four (A) or two (B) separate experiments. * designates values significantly reduced (p < 0.01) when comparing cells challenged with or without GE2.

 
Fc{gamma}RII-Fc{epsilon}RI Co-aggregation Inhibits CBMCs Fc{epsilon}RI-mediated TNF-{alpha} Production—Human mast cells produce TNF-{alpha} following IgE-mediated stimulation (21). The results in Fig. 2B show that anti-NIP IgE-sensitized CBMCs that were treated with GE2 released significantly less TNF-{alpha} in response to 12-h stimulation with NIP/BSA compared with sensitized but GE2-untreated cells. The average inhibition of Fc{epsilon}RI-mediated TNF-{alpha} production by Fc{gamma}RII-Fc{epsilon}RI co-aggregation was 60 and 64% using 5 and 10 µg/ml, respectively.

Fc{gamma}RII-Fc{epsilon}RI Co-aggregation Inhibits CBMCs Fc{epsilon}RI-mediated Ca2+ Mobilization—Previous studies have indicated that human mast cell Fc{epsilon}RI-mediated degranulation and cytokine production both depend on the release of Ca2+ from intracellular stores and on the subsequent sustained influx of extracellular Ca2+ (22, 23). We used the Ca2+ indicator dye Indo-1 and FACS analysis to examine the pattern of Fc{epsilon}RI-mediated Ca2+ mobilization in human mast cells following GE2 treatment (Fig. 3).

Cross-linking anti-NIP IgE-primed Fc{epsilon}RI with NIP/BSA leads, after a lag phase, to a rapid increase in intracellular Ca2+ levels (Fig. 3A). This Ca2+ spike is followed by a sustained elevation in Ca2+ levels, the Ca2+ plateau, which persists for up to 3 min. In the experiment shown in Fig. 3A, the lag time from antigen addition to Fc{epsilon}RI-mediated Ca2+ influx was ~24 s. When cells were treated with GE2 prior to antigen challenge, the lag time from antigen addition to the initial rise in [Ca2+] more than doubled to 60 s. Thus, co-aggregating Fc{gamma}RII and Fc{epsilon}RI with GE2 decreases the initial Ca2+ mobilization in human mast cells.

To further investigate whether co-aggregation inhibits the release of intracellular calcium stores, we utilized thapsigargin, which induces an increase in [Ca2+]i because of store leakage from the endoplasmic reticulum. As seen in Fig. 3B, thapsigargin induced a sustained increase in [Ca2+]i. However, when GE2 (10 µg/ml) and antigen were added prior to challenge with thapsigargin, the increase observed in [Ca2+]i was smaller, and a sustained phase of Ca2+ was lacking. These findings indicate that the effect of GE2 appeared to be mainly due to an inhibition of the endoplasmic reticulum Ca2+ store as well as sustained, store-dependent [Ca2+]i influx.

Fc{gamma}RII-Fc{epsilon}RI Co-aggregation Inhibits CBMCs Fc{epsilon}RI-mediated Morphological Changes—Under transmission electron microscopy, unstimulated cultured human mast cells (Fig. 4A) show large unsegmented nuclei and relatively sparse endoplasmic reticulum and mitochondria. Granules are numerous and contain loosely packed matrix material plus occasional dense core material, multilamellar membranes, and internal vesicles. Fig. 4B shows the intracellular fusion of granules (arrows) and the extracellular release of granule contents associated with normal IgE-mediated mast cell activation (24–26). In contrast, the granules in cells treated with GE2 remain individual and intact following antigen stimulation (Fig. 4C).



View larger version (124K):
[in this window]
[in a new window]
  		FIG. 4.
Fc{gamma}RII-Fc{epsilon}RI co-aggregation inhibits Fc{epsilon}RI-mediated morphological changes in CBMCs. Unstimulated (A) CBMCs show characteristic morphological features of mast cells with numerous intact cytoplasmic granules (arrows). Fc{epsilon}RI cross-linking induces granule-granule fusion in non-GE2-challenged (arrows in B) but not in GE2-challenged (C) CBMCs. Magnification is x8,000.

 
Fc{gamma}RII-Fc{epsilon}RI Co-aggregation Affects Fc{epsilon}RI-mediated Tyrosine Phosphorylation of Multiple Substrates—Protein tyrosine phosphorylation is a key event linking Fc{epsilon}RI cross-linking to downstream signaling in human mast cells and basophils (15, 16, 23). To investigate the effects of co-aggregating Fc{gamma}RII-Fc{epsilon}RI on IgE-mediated protein tyrosine phosphorylation, whole cell lysates of IgE-activated cells, with or without GE2 preincubation, were resolved by SDS-PAGE and probed with anti-Tyr(P) antibodies. As shown in Fig. 5A, NIP/BSA cross-linking of anti-NIP IgE-sensitized Fc{epsilon}RI induced the tyrosine phosphorylation of several different substrates at 2, 5, and 15 min (lanes 2, 4, and 6) compared with non-activated cells (lane 1). The most prominent signals were species appearing at ~110, 85, 76, 72, 66, 44, 42, 38, and 28 kDa. When cells were treated with GE2, tyrosine phosphorylation of several of these substrates was reduced. These included proteins with molecular masses of ~85, 72, 66, 44, and 38 kDa (indicated with arrows). Thus, the down-regulation of IgE-mediated degranulation by co-aggregation of Fc{gamma}RII and Fc{epsilon}RI by GE2 appears to involve the reduction of tyrosine phosphorylation of several different proteins.



View larger version (58K):
[in this window]
[in a new window]
  		FIG. 5.
A, differential cellular phosphorylation induced by Fc{gamma}RII-Fc{epsilon}RI co-aggregation. IgE-sensitized CBMCs were incubated with NIP/BSA (200 ng/ml) for the indicated time with or without GE2 preincubation. Cells were lysed as described under "Experimental Procedures," and proteins in the cleared cell lysates were analyzed by SDS-PAGE (1.3 x 106 cell equivalents/lane). Proteins were transferred onto nitrocellulose membranes and probed with antiphosphotyrosine (pY) Ab. Immunoreactivity was detected using ECL. The arrows on the left indicate tyrosine-phosphorylated proteins differentially phosphorylated in GE2- and non-GE2-challenged cells (top blot). To ensure equal protein loading, blots were stripped and reprobed with 1 µg/ml anti-actin Ab as described above (bottom blot). Similar results were obtained with two other separate experiments. B, Fc{gamma}RII-Fc{epsilon}RI co-aggregation inhibits Fc{gamma}RI-mediated Syk kinase phosphorylation. Cells were lysed, and the clarified supernatants were immunoprecipitated (IP) with anti-Syk antibodies. Immunoprecipitates were analyzed by Western blotting with antiphosphotyrosine Abs (top), stripped, and reprobed with anti-Syk Ab. Each lane shows Syk immunoprecipitated from 2.8 x 105 cells. The results are representative of two separate experiments.

 
Previous investigations have shown that the tyrosine kinase Syk is quickly phosphorylated in IgE-stimulated human Fc{epsilon}RI-positive cells (15, 23, 27). In human basophils, co-aggregation of Fc{epsilon}RI and Fc{gamma}RII with antigen-specific IgE and IgG (7) or GE2 (9) inhibits the tyrosine phosphorylation of Syk. As seen in Fig. 5B using whole cell lysates of CBMCs, co-aggregation by GE2 reduced the tyrosine phosphorylation of a protein with the approximate molecular mass of Syk (~72 kDa). Thus, we wanted to examine specifically the phosphorylation of Syk in GE2-treated CBMCs after IgE stimulation. Cells with or without GE2 preincubation were stimulated for the indicated periods and lysed, and anti-Syk immunoprecipitates were analyzed by immunoblotting with anti-Tyr(P) Ab. As seen in Fig. 5B Syk was tyrosine-phosphorylated within 2 min after addition of antigen. The amount of Syk tyrosine phosphorylation was markedly reduced in IgE-activated cells that had been treated with GE2 compared with non-treated IgE-activated cells.

Grb2 Phosphorylation Is Increased in Resting and Fc{gamma}RII-Fc{epsilon}RI-co-aggregated Cells—Grb2 is an adapter protein associated with Fc{epsilon}RI and Fc{gamma}RIIB signaling (28, 29). Initial experiments indicated Grb2 was differentially phosphorylated and associated with other signaling molecules under Fc{epsilon}RI-Fc{gamma}RIIB-co-aggregating conditions (not shown). Grb2 was immunoprecipitated from lysates of variously activated cells, and immune complexes were resolved by SDS-PAGE and probed with anti-Tyr(P) Abs. As seen in Fig. 6, in unstimulated cells Grb2 immunoprecipitated tyrosine-phosphorylated proteins with apparent molecular masses of 60–65, 54–60, 35–37, and 20–25 kDa. Upon antigen-driven Fc{epsilon}RI cross-linking, the interaction of Grb2 with the phosphorylated species at 20–25 and 60–65 kDa was significantly reduced. However, these reductions were not observed when antigen-treated cells had been treated with GE2 so as to drive Fc{epsilon}-Fc{gamma} co-aggregation. Stripping and reprobing with anti-Grb2 antibodies determined that the molecular mass species at about 25 kDa was Grb2 (Fig. 6, bottom blot). The increased phosphorylation of Grb2 in resting versus IgE-stimulated cells suggests that Grb2 phosphorylation is important for preventing Fc{epsilon}RI activation and for inhibitory signaling.



View larger version (75K):
[in this window]
[in a new window]
  		FIG. 6.
Fc{gamma}RII-Fc{epsilon}RI co-aggregation induces differential Grb2 phosphorylation and association of several signaling proteins. CBMCs were lysed, and the clarified supernatants were immunoprecipitated with anti-Grb2 antibodies. Immunoprecipitates were analyzed by Western blotting with anti-Tyr(P) (pY) Abs (top blot) and were stripped and reprobed with anti-Grb2 Abs (bottom blot). The arrows on the left indicate tyrosine-phosphorylated proteins differentially phosphorylated in GE2- and non-GE2-challenged cells. Each lane shows Grb2 immunoprecipitated from 8.0 x 105 cells. The results are representative of five separate experiments.

 
Phosphorylated Grb2 and Dok Complexes Are Increased in Resting and Fc{gamma}RII-Fc{epsilon}RI-co-aggregated Cells—We hypothesized that the 60–65-kDa species complexed to Grb2 was Dok. Grb2 was immunoprecipitated, and the blots were probed with anti-Tyr(P) Abs. Confirming the results seen in Fig. 6, top blot, the phosphorylation of the 60–65-kDa species was reduced under IgE-cross-linking conditions. However, in resting and co-aggregated cells a stronger phosphorylation signal was observed (Fig. 7, top). Probing with anti-Dok Abs revealed that the Dok-Grb2 interaction was incrementally lost upon IgE activation but was maintained and slightly increased in resting and Fc{epsilon}-Fc{gamma}-co-aggregated cells (Fig. 7, middle). This difference was not because of unequal protein loading as shown in the Grb2 blot (Fig. 7, bottom). Studies are underway to determine the identity of the 35–40- and 50–55-kDa proteins, but linker for activation of T cells (LAT) and Shc are likely candidates, respectively. Nonetheless, Grb2 and Dok appear to form a phosphorylation-dependent complex in resting mast cells that is lost upon activation but is maintained and slightly increased under Fc{epsilon}-Fc{gamma} inhibitory signaling.



View larger version (48K):
[in this window]
[in a new window]
  		FIG. 7.
Fc{gamma}RII-Fc{epsilon}RI co-aggregation induces Dok phosphorylation and Grb2 interaction. CBMCs were lysed, and the clarified supernatants were immunoprecipitated with anti-Grb2 Abs. Immunoprecipitates were analyzed by Western blotting with anti-Tyr(P) (pY) Abs (top), stripped, and reprobed with anti-Dok (middle) and anti-Grb2 (bottom) Abs. Each lane shows Grb2 immunoprecipitated from 3.6 x 105 cells. The results are representative of two separate experiments. NRIg, normal rabbit IgG.

 
Phosphorylated SHIP and Dok Complexes Are Increased in Resting and Fc{gamma}RII-Fc{epsilon}RI-co-aggregated Cells—Rodent studies suggest that SHIP may mediate Fc{gamma}RII inhibitory function in mast cells through the recruitment of Dok (30). Dok was immunoprecipitated from cells as described above, and blots were probed with anti-Tyr(P) Abs. As seen in Fig. 8A, a phosphorylated protein shown to be SHIP (middle) at an apparent molecular mass of 145 kDa was differentially tyrosine-phosphorylated in resting, Fc{epsilon}-, and Fc{epsilon}-Fc{gamma}-stimulated cells (top). Specifically, the strong basal tyrosine phosphorylation was decreased in IgE-stimulated cells at 2, 5, and 15 min. However, the tyrosine phosphorylation was increased in Fc{epsilon}-Fc{gamma}-stimulated cells at 5 and 15 min. In addition, immunoblot analysis of Dok immunoprecipitations using antiphosphotyrosine Abs demonstrated that Dok is constitutively phosphorylated on tyrosine at a low level in unstimulated cells, and phosphorylation is enhanced following aggregation of Fc{epsilon}RI alone. Ras-GAP was found to associate with Dok in unstimulated and GE2-co-aggregated cells (Fig. 8B). Thus, in human mast cells, tyrosine-phosphorylated SHIP may exert its gatekeeper role (31) through its interaction with Dok. By binding to Dok, SHIP may negatively regulate Ras function by enhancing its intrinsic GTPase activity through RasGAP.



View larger version (74K):
[in this window]
[in a new window]
  		FIG. 8.
A, Fc{gamma}RII-Fc{epsilon}RI co-aggregation induces Dok-associated SHIP phosphorylation. CBMCs were antigen-activated for the indicated times with or without preincubation with GE2. Cells were lysed, and the clarified supernatants were immunoprecipitated (IP) with anti-Dok Abs. Immunoprecipitates were analyzed by Western blotting with anti-Tyr(P) (pY) Abs (A, top), stripped, and reprobed with anti-SHIP (A, middle) and anti-Dok (A, bottom) Abs. Each lane shows Dok immunoprecipitated from 4.9 x 105 cells. B, Fc{gamma}RII-Fc{epsilon}RI co-aggregation induces Dok-associated RasGAP phosphorylation. CBMCs were treated as above and probed with anti-Tyr(P) followed by anti-RasGAP Abs. Each lane represents 5.6 x 105 cells. NRIg, normal rabbit IgG. The results are representative of two separate experiments.

 
IgE Sensitization Alone Induces Degranulation in Dok Knock-out Bone Marrow Mast Cells—The data presented above suggest that Dok may play a role in setting the threshold for degranulation in mast cells. To determine whether Dok was involved in maintaining Fc{epsilon}RI in a quiescent state, we investigated the effects that IgE binding alone had on BMMCs from Dok knock-out mice that have been described previously (32, 33). As seen in Fig. 9, degranulation of Dok knock-out BMMCs was observed simply with the addition of IgE clones from either of two different murine clones. Degranulation from these cells did not follow exposure to mouse IgG, nor did wild type BMMCs undergo degranulation following exposure to the same IgE. Taken together, these studies demonstrate a vital role for Dok in setting the threshold for degranulation in mast cells.



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 9.
IgE alone induces degranulation in Dok knock-out BMMCs. BMMCs from Dok+/+ or Dok–/– were challenged with varying concentrations of mouse IgE or IgG and centrifuged, and the supernatant was removed for the analysis of {beta}-hexosaminidase as described previously (61). The results are representative of three separate experiments.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The ability of Fc{gamma}RII to down-regulate human basophil Fc{epsilon}RI-induced degranulation was first reported by Daeron and co-workers (4) and confirmed in later studies (7). Based on our recent studies using human basophils and a novel chimeric human Fc{gamma}-Fc{epsilon} Ig protein (9), we chose to focus on the use of ITIM/ITAM-receptor cross-linking as a way to block the initiation of the Fc{epsilon}RI response in mast cells. Because mast cells are clearly a distinct lineage from basophils in humans and have a number of distinctive functional properties in mediating human disease (34), it is very important to demonstrate their specific response to Fc{gamma}RII-Fc{epsilon}RI co-aggregation. We report here that co-aggregating Fc{gamma}RII and Fc{epsilon}RI on human mast cells inhibits Fc{epsilon}RI-induced mediator release. These results provide the first demonstration of antigen-specific down-regulation of Fc{epsilon}RI-mediated signaling though Fc{gamma}RII-Fc{epsilon}RI co-aggregation on human mast cells.

Here, we confirm that human mast cells express CD32 (Fc{gamma}RII) but not CD16 (Fc{gamma}RIII) or CD64 (Fc{gamma}RI). Although CBMCs contained RNA transcripts for all three Fc{gamma}RII isoforms, we were not able to detect Fc{gamma}RIIA protein expression by FACS analysis with Ab IV.3 or by Western blotting with an Ab raised against the cytoplasmic tail of Fc{gamma}RIIA. It is still possible that there is donor variability in Fc{gamma}RII expression in human mast cells as has been shown in human monocytes (35), platelets (36), and NK cells (19). Human monocytes can also alter Fc{gamma}RII isoform expression in response to certain cytokines and culture conditions (37). Indeed, we have encountered periodically human Fc{epsilon}RI-positive cell preparations that did not respond to negative signaling, and we are investigating the relationship between Fc{gamma}RII isoform expression and the ability of CBMCs to undergo co-aggregation and inhibition of Fc{epsilon}RI signaling.

Granule secretion and cytokine production are both Ca2+-dependent processes in human mast cells. We found the lag time between antigen addition and initial Ca2+ mobilization very similar to those reported previously using cultured human mast cells (23, 38). However, as with human basophils (7), GE2-driven Fc{gamma}RII-Fc{epsilon}RI co-aggregation extended the lag time from Fc{epsilon}RI cross-linking to the Ca2+ spike response and reduced the magnitude of the Ca2+ plateau. In addition, GE2 appears to inhibit the release of intracellular calcium stores as thapsigargin-induced release was inhibited by GE2. Co-aggregation of Fc{gamma}RII-BCR on B cells under a variety of co-cross-linking conditions results in premature termination of Ca2+ influx, sometimes associated with a reduced Ca2+ spike response but not an increased delay to the spike response (39–42). This difference between mast cells/basophils and B cells is unexplained but likely reflects distinct signaling properties of B cells and human Fc{epsilon}RI-positive cells and particularly the presence of Fc{gamma}RIIA on resting and activated B cells.

Tyrosine phosphorylation of cellular substrates is an integral part of IgE-mediated signaling in human mast cells (38) and basophils (7). Several substrates were differentially phosphorylated upon antigen activation in CBMCs (Fig. 5A). We reported previously that the tyrosine kinase Syk is critical in human basophil IgE-mediated signal transduction (15, 16) and that co-aggregation inhibits Syk phosphorylation (7, 9). Here we show little or no tyrosine-phosphorylated Syk present in resting mast cells, whereas Fc{epsilon}RI cross-linking induced a large increase in Syk phosphorylation (Fig. 5B). The kinetics of phosphorylation observed upon IgE activation were similar to previous reports using human mast cells (23). As with human basophils, Syk phosphorylation was markedly decreased by co-aggregating Fc{gamma}RII and Fc{epsilon}RI.

Surprisingly, we observed increased Grb2 phosphorylation in resting and Fc{gamma}RII-Fc{epsilon}RI-co-aggregated cells with reduced Grb2 phosphorylation seen in mast cells activated through Fc{epsilon}RI alone. We are not aware of any studies that associate Grb2 tyrosine phosphorylation with inhibitory Fc{epsilon}RI signaling. Grb2 functions as an adaptor protein associated with protein-tyrosine kinase signaling (43). Published studies, mostly nonphysiological, focus on the phosphorylation of other signaling intermediates, which then leads to the binding of Grb2 SH2 and SH3 domains. The tyrosine phosphorylation of Grb2 itself and the effect on signaling responses have not been characterized, especially in human mast cells. However, Grb2 protein has several tyrosines capable of being phosphorylated (44), and Grb2 tyrosine phosphorylation has been detected under physiological conditions in several cell types (45–47). Analogous to our findings, Grb2 tyrosine phosphorylation was clearly shown to negatively regulate the downstream activation of tyrosine kinase signaling pathways in other cell types (48). Our data support these previous studies and suggest that tyrosine phosphorylation of Grb2 may be an important step in a novel mechanism of down-regulation of Fc{epsilon}RI activation of human mast cells.

We also found that Dok is involved in IgE receptor signaling in human mast cells. Similar to Grb2, Dok phosphorylation was reduced in Fc{epsilon}RI-stimulated cells, whereas it was maintained in co-aggregated "inhibited" cells. The increase in Dok tyrosine phosphorylation was also associated with increased interaction with Grb2. Previous studies have shown that Grb2 SH2 domains can bind to phosphorylated Dok (and a phosphorylated 30–40-kDa protein, as we also found) (Fig. 6) (49). Reports with transfected RBL-2H3 cells demonstrated that co-aggregation of Fc{gamma}RII with Fc{epsilon}RI stimulates enhanced SHIP tyrosine phosphorylation leading to association with Shc and Dok. An increase in Dok phosphorylation was observed under co-aggregation conditions, with subsequent increased association with RasGAP (33). Similarly, co-aggregating Fc{gamma}RII with Fc{epsilon}RI on B cells leads to increased tyrosine phosphorylation of Dok associated with negative signaling (50, 51). Dok also plays a negative role at multiple steps in T cell signaling (37) and through the ITIM-containing mast cell function-associated antigen (MAFA) receptor on RBL-2H3 cells (52). Overall, our data also support a role for Dok in inhibitory signaling through Fc{gamma}RIIB via its increased association with Grb2 and SHIP.

We observed Dok-Grb2 interaction in non-activated cells, interaction that was decreased at 2 and 5 min in IgE-activated cells and completely absent at 15 min. Thus tyrosine-phosphorylated Dok-Grb2 appears to be important for maintaining Fc{epsilon}RI in its unactivated state and suggests a previously unrecognized gatekeeper role for Dok and Grb2 in human mast cells. This contrasts with a rodent study that found that Dok is not needed for Fc{gamma}RIIB-mediated inhibitory signaling in Dok-deficient mast cells (33), suggesting that another molecule can compensate for loss of Dok or that, as in other signaling systems, there are important differences between rodents and humans.

We have confirmed rodent studies in which Dok was found to interact with SHIP and in which co-aggregation of Fc{epsilon} with Fc{gamma} led to increased SHIP phosphorylation (33, 53). We observed a high basal tyrosine phosphorylation of Dok-associated SHIP in resting cells that was slightly decreased in IgE-activated (Fc{epsilon}RI-cross-linked) cells. RBL-2H3 cells have also been shown to exhibit high basal tyrosine phosphorylation of SHIP (33). Others have reported an increase in tyrosine phosphorylation of SHIP following Fc{epsilon}RI cross-linking (33). It is possible under these conditions that SHIP is recruited away from Dok and to the Fc{epsilon}RI {beta} chain (33, 54, 55) to regulate Fc{epsilon}RI signaling through an Fc{gamma}RII-independent mechanism. We are currently examining this hypothesis.

Our data using Dok knock-out BMMCs further point to a role for Dok in the Fc{gamma}RIIB-mediated inhibition of IgE-Fc{epsilon}RI degranulation. We found that monomeric IgE alone induced degranulation in these cells. Previous studies found similar results in SHIP knock-out mast cells, although the maximal degranulation we observed ({approx}30%) was lower than that in the SHIP knockouts ({approx}80%) (31). This suggests that Dok contributes to the process of BMMCs IgE receptor quiescence, but other factors are also needed, probably SHIP. To this end, Ott et al. (33) found Dok was sufficient, but not necessary, for Fc{gamma}RIIB inhibitory signaling in BMMCs from Dok knock-out mice. Taken together, these results suggest that Dok, through its interaction with Grb2 and SHIP, keeps Fc{epsilon}RI in a quiescent state and that this inhibitory complex is maintained under co-aggregating conditions.

We confirm previous studies that implicate SHIP in Fc{gamma}RII-induced inhibition of Fc{epsilon}RI signaling. The absence of SHIP in mice leads to increased releasability of BMMCs, even during IgE sensitization (31). In human Fc{epsilon}RI studies, Vonakis et al. (56) found a strong negative correlation between the amount of SHIP protein and maximal degranulation in human basophils. Although our results showing reduced Syk phosphorylation support a role for inhibitory signaling by SHP-1 (57), SHIP activation also appears to be important in our human mast cell system. Given that Fc{gamma}RIIB can interact with both SHP-1 and SHIP (58, 59), it is still unclear which phosphatase plays the more dominant role in down-regulating Fc{epsilon}RI in human mast cells. It is quite possible that multiple phosphorylation sites in Fc{gamma}RIIB, where phosphatase binding occurs, contribute uniquely to transduction of Fc{gamma}RIIB-mediated inhibitory signals.

Tyrosine phosphorylation of Grb2 and the differential binding of Dok and SHIP may regulate inhibitory function through several different mechanisms. Grb2 may help to localize Dok and/or SHIP to the cell membrane, regulating their inhibitory function. It is well established that SHIP can inhibit Fc{epsilon}RI functional and biochemical responses (60), but it is not as clear how SHIP exerts such effects. Dok tyrosine phosphorylation (or enhanced SHIP tyrosine phosphorylation) may facilitate the recruitment of Dok (through Grb2 as seen in Fig. 7) to the Fc{epsilon}RI-Fc{gamma}RII receptor complex. Indeed, Dok recruitment to Fc{epsilon}RI is enough to inhibit Fc{epsilon}RI-induced signal transduction (30). Thus, because SHIP and Dok can associate with RasGAP under co-aggregating conditions (33, 50), Fc{epsilon}RI may be "turned off" by up-regulating Ras GTPase activity. Our findings suggest that the mechanisms that keep Fc{epsilon}RI in its non-activated state are similar to the mechanisms of inhibition through Fc{epsilon}RI-Fc{gamma}RIIB co-aggregation.

Many investigators have sought inhibitors of human Fc{epsilon}RI signaling to block IgE-mediated allergic inflammation. One approach is to block Fc{epsilon}RI signaling by altering the propagation of signals generated from the cross-linked receptors. Strategies based on the specific inhibition of the earliest events in the Fc{epsilon}RI signaling cascade, such as we have shown here using GE2 to co-aggregate Fc{epsilon}RI with Fc{gamma}RII, may ultimately generate new therapies for allergic inflammation. In addition to Fc{gamma}RII, we also demonstrate that CBMCs also express the ITIM-containing receptors CD22 and CD81. We did not detect other ITIM-receptor expression on mast cells but were limited to those which had Abs detecting human isoforms. CD22 is widely known for its ability to down-regulate B cell receptor-mediated B cell activation (62), whereas CD81 negatively regulates Fc{epsilon}RI responses in rodent mast cells (63). These and other ITIM-containing receptors on human mast cells are also potential novel targets for chimeric bifunctional proteins to "down-regulate" Fc{epsilon}RI function as described here.

In summary, we have demonstrated that IgE activation of cultured human mast cells can be inhibited by co-aggregating Fc{epsilon}RI with Fc{gamma}RII through a novel mechanism involving Grb2, Dok, and SHIP. By achieving this with a human chimeric immunoglobulin, we have sought to turn off allergic responses utilizing the powerful negative regulatory ability of ITIM receptor motifs. The highly specific and avid association of Fc and Fc{epsilon}RI provides a highly specific target by which to deliver the off switch to effector cells of allergy and asthma. This approach can be extended in several ways. Firstly, chimeric proteins capable of binding more that one ITIM receptor (e.g. G-G-E2 or CD81L-G-E2) may be more potent inhibitors. Secondly, it is possible to make chimeric allergen-{gamma} proteins that will bind to Fc{gamma}RII and indirectly bind to Fc{epsilon}RI via their high affinity interaction with the antigen-specific IgE on the mast cells. Not only would this latter approach serve to inhibit antigen-specific immediate reactivity, but also it should be able to provide a platform for safer and more effective allergen immunotherapy. As such, these improved versions of the chimeric protein described may prove to be promising agents for the treatment of human allergic disorders.


   FOOTNOTES
 
* This work was supported in part by National Institutes of Health Grants P50 HL56384, RO1-AI15251, RO1 GM49814, RO3 TW00440, and RO1 AI42204. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ Supported by an American Lung Association grant and by a Parker B. Francis Fellowship in Pulmonary Research. To whom correspondence should be addressed: Dept. of Internal Medicine, Division of Rheumatology, Allergy, and Immunology, P. O. Box 263, MCV Station, Richmond, VA 23298. Tel.: 804-828-9685; Fax: 804-828-0283; E-mail: clkepley{at}mail1.vcu.edu.

1 The abbreviations used are: Fc{epsilon}RI, high affinity receptor for IgE; Fc{epsilon}R, receptor for IgE; Fc{gamma}R, receptor for IgG; ITAM, immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor tyrosine-based inhibitory motif; BCR, B cell receptor; SHIP, SH2 domain containing inositol 5-phosphatase; Ab, antibody; mAb, monoclonal antibody; NIP, 3-nitro-4-hydroxy-5-iodophenylacetate; PBS, phosphate-buffered saline; BSA, bovine serum albumin; PBS/BSA, phosphate-buffered saline with 0.1% bovine serum albumin; HBSS, Hanks' balanced salt solution; FACS, fluorescence-activated cell sorter; CBMCs, cord blood-derived human mast cells; TNF-{alpha}, tumor necrosis factor-{alpha}; RasGAP, Ras GTPase-activating protein; BMMCs, bone marrow-derived mast cells; SHP-1, Src homology domain containing protein-tyrosine phosphatase-1. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Turner, H., and Kinet, J. P. (1999) Nature 402, B24–B30[CrossRef][Medline] [Order article via Infotrieve]
  2. Muta, T., Kurosaki, T., Misulovin, Z., Sanchez, M., Nussenzweig, M. C., and Ravetch, J. V. (1994) Nature 368, 70–73[CrossRef][Medline] [Order article via Infotrieve]
  3. D'Ambrosio, D., Hippen, K. L., Minskoff, S. A., Mellman, I., Pani, G., Siminovitch, K. A., and Cambier, J. C. (1995) Science 268, 293–297[Abstract/Free Full Text]
  4. Daeron, M., Malbec, O., Latour, S., Arock, M., and Fridman, W. H. (1995) J. Clin. Investig. 95, 577–585[Medline] [Order article via Infotrieve]
  5. Daeron, M., Latour, S., Malbec, O., Espinosa, E., Pina, P., Pasmans, S., and Fridman, W. H. (1995) Immunity 3, 635–646[CrossRef][Medline] [Order article via Infotrieve]
  6. Malbec, O., Fong, D. C., Turner, M., Tybulewicz, V. L. J., Cambier, J. C., Fridman, W. H., and Daeron, M. (1998) J. Immunol. 160, 1647–1658[Abstract/Free Full Text]
  7. Kepley, C. L., Cambier, J. C., Morel, P. A., Lujan, D., Ortega, E., Wilson, B. S., and Oliver, J. M. (2000) J. Allergy Clin. Immunol. 106, 337–348[CrossRef][Medline] [Order article via Infotrieve]
  8. Ravetch, J. V., and Lanier, L. L. (2000) Science 290, 84–89[Abstract/Free Full Text]
  9. Zhu, D., Kepley, C. L., Zhang, M., Zhang, K., and Saxon, A. (2002) Nat. Med. 8, 518–521[CrossRef][Medline] [Order article via Infotrieve]
  10. Yamada, T., Zhu, D., Zhang, K., and Saxon, A. (2003) J. Biol. Chem. 278, 32818–32824[Abstract/Free Full Text]
  11. Kepley, C. L., Zhang, K., Zhu, D., and Saxon, A. (2003) Clin. Immunol. 108, 89–94[CrossRef][Medline] [Order article via Infotrieve]
  12. Riske, F., Hakim, J., Mallamaci, M., Griffin, M., Pilson, B., Tobkes, N., Lin, P., Danho, W., Kochan, J., and Chizzonite, R. (1991) J. Biol. Chem. 266, 11245–11251[Abstract/Free Full Text]
  13. Yamaguchi, M., Sayama, K., Yano, K., Lantz, C. S., Noben-Trauth, N., Ra, C., Costa, J. J., and Galli, S. J. (1999) J. Immunol. 162, 5455–5465[Abstract/Free Full Text]
  14. Irani, A.-M. A., Bradford, T. R., Kepley, C. L., Schechter, N. M., and Schwartz, L. B. (1989) J. Histochem. Cytochem. 37, 1509–1515[Abstract/Free Full Text]
  15. Kepley, C. L., Wilson, B. W., and Oliver, J. M. (1998) J. Allergy Clin. Immunol. 102, 304–315[CrossRef][Medline] [Order article via Infotrieve]
  16. Kepley, C. L., Youseff, L., Andrews, R. P., Wilson, B. S., and Oliver, J. M. (1999) J. Allergy Clin. Immunol. 104, 279–284[CrossRef][Medline] [Order article via Infotrieve]
  17. Okayama, Y., Kirshenbaum, A. S., and Metcalfe, D. D. (2000) J. Immunol. 164, 4332–4339[Abstract/Free Full Text]
  18. Daeron, M. (1997) Annu. Rev. Immunol. 15, 203–234[CrossRef][Medline] [Order article via Infotrieve]
  19. Metes, D., Ernst, L. K., Chambers, W. H., Sulica, A., Herberman, R. B., and Morel, P. A. (1998) Blood 91, 2369–2380[Abstract/Free Full Text]
  20. Lyden, T. W., Robinson, J. M., Tridandapani, S., Teillaud, J. L., Garber, S. A., Osborne, J. M., Frey, J., Budde, P., and Anderson, C. L. (2001) J. Immunol. 166, 3882–3889[Abstract/Free Full Text]
  21. Galli, S. J. (1993) N. Engl. J. Med. 328, 257–265[Free Full Text]
  22. MacGlashan, D., Jr., and Guo, C.-B. (1991) J. Immunol. 147, 2259–2269[Abstract]
  23. Suzuki, H., Takei, M., Yanagida, M., Nakahata, T., Kawakami, T., and Fukamachi, H. (1997) J. Immunol. 159, 5881–5888[Abstract]
  24. Eguchi, M. (1991) Electron Microsc. Rev. 4, 293–318[CrossRef][Medline] [Order article via Infotrieve]
  25. Furitsu, T., Saito, H., Dvorak, A., Schwartz, L. B., Irani, A. A., Burdick, J. F., Ishizaka, K., and Ishizaka, T. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 10039–10043[Abstract/Free Full Text]
  26. Dvorak, A. M., Furitsu, T., and Ishizaka, T. (1993) Int. Arch. Allergy Immunol. 100, 219–229[CrossRef][Medline] [Order article via Infotrieve]
  27. Lavens-Phillips, S. E., and MacGlashan, D. W. (2000) Am. J. Respir. Cell Mol. Biol. 23, 566–571[Abstract/Free Full Text]
  28. Turner, H., Reif, K., Rivera, J., and Cantrell, D. A. (1995) J. Biol. Chem. 270, 9500–9506[Abstract/Free Full Text]
  29. Tridandapani, S., Kelley, T., Cooney, D., Pradhan, M., and Coggeshall, K. M. (1997) Immunol. Today 18, 424–427[CrossRef][Medline] [Order article via Infotrieve]
  30. Matricardi, P. M., and Ronchetti, R. (2001) Curr. Opin. Allergy Clin. Immunol. 1, 413–419[CrossRef][Medline] [Order article via Infotrieve]
  31. Huber, M., Helgason, C. D., Damen, J. E., Liu, L., Humphries, R. K., and Krystal, G. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11330–11335[Abstract/Free Full Text]
  32. Di Cristofano, A., Niki, M., Zhao, M., Karnell, F. G., Clarkson, B., Pear, W. S., Van Aelst, L., and Pandolfi, P. P. (2001) J. Exp. Med. 194, 275–284[Abstract/Free Full Text]
  33. Ott, V. L., Tamir, I., Niki, M., Pandolfi, P. P., and Cambier, J. C. (2002) J. Immunol. 168, 4430–4439[Abstract/Free Full Text]
  34. Schwartz, L. B., and Huff, T. F. (1993) in Allergy: Principles and Practice (Middleton, E., Jr., Reed, C. E., Ellis, E. F., Adkinson, N. F., Jr., Yunginger, J. W., and Busse, W. W., eds) pp. 135–168, Mosby, St. Louis, MO
  35. Gosselin, E. J., Brown, M. F., Anderson, C. L., Zipf, T. F., and Guyre, P. M. (1990) J. Immunol. 144, 1817–1822[Abstract]
  36. Rosenfeld, S. I., Ryan, D. H., Looney, R. J., Anderson, C. L., Abraham, G. N., and Leddy, J. P. (1987) J. Immunol. 138, 2869–2873[Abstract]
  37. Nemorin, J. G., Laporte, P., Berube, G., and Duplay, P. (2001) J. Immunol. 166, 4408–4415[Abstract/Free Full Text]
  38. Tkaczyk, C., and Gilfillan, A. M. (2001) Clin. Immunol. 99, 198–210[CrossRef][Medline] [Order article via Infotrieve]
  39. Kiener, P. A., Lioubin, M. N., Rohrschneider, L. R., Ledbetter, J. A., Nadler, S. G., and Diegel, M. L. (1997) J. Biol. Chem. 272, 3838–3844[Abstract/Free Full Text]
  40. Hippen, K. L., Buhl, A. M., D'Ambrosio, D., Nakamura, K., Persin, C., and Cambier, J. C. (1997) Immunity 7, 49–58[CrossRef][Medline] [Order article via Infotrieve]
  41. Ono, M., Okada, S., Tanagi, S., Kurosaki, T., and Ravetch, J. V. (1997) Cell 90, 293–301[CrossRef][Medline] [Order article via Infotrieve]
  42. Budde, P., Bewarder, N., Weinrich, V., Schulzeck, O., and Frey, J. (1994) J. Biol. Chem. 269, 30636–30644[Abstract/Free Full Text]
  43. Pawson, T., and Scott, J. D. (1997) Science 278, 2075–2080[Abstract/Free Full Text]
  44. Stern, M. J., Marengere, L. E., Daly, R. J., Lowenstein, E. J., Kokel, M., Batzer, A., Olivier, P., Pawson, T., and Schlessinger, J. (1993) Mol. Biol. Cell 4, 1175–1188[Abstract]
  45. Benjamin, C. W., Linseman, D. A., and Jones, D. A. (1994) J. Biol. Chem. 269, 31346–31349[Abstract/Free Full Text]
  46. Ghosh, J., and Miller, R. A. (1995) Mech. Ageing Dev. 80, 171–187[CrossRef][Medline] [Order article via Infotrieve]
  47. Li, S., Couvillon, A. D., Brasher, B. B., and Van Etten, R. A. (2001) EMBO J. 20, 6793–6804[CrossRef][Medline] [Order article via Infotrieve]
  48. Platts-Mills, T. A., Perzanowski, M., Woodfolk, J. A., and Lundback, B. (2002) Clin. Exp. Allergy 32, 335–338, 1259[CrossRef][Medline] [Order article via Infotrieve]
  49. Robinson, A., Gibbins, J., Rodriguez-Linares, B., Finan, P. M., Wilson, L., Kellie, S., Findell, P., and Watson, S. P. (1996) Blood 88, 522–530[Abstract/Free Full Text]
  50. Tamir, I., Stolpa, J. C., Helgason, C. D., Nakamura, K., Bruhns, P., Daeron, M., and Cambier, J. C. (2000) Immunity 12, 347–358[CrossRef][Medline] [Order article via Infotrieve]
  51. Yamanashi, Y., Tamura, T., Kanamori, T., Yamane, H., Nariuchi, H., Yamamoto, T., and Baltimore, D. (2000) Genes Dev. 14, 11–16[Abstract/Free Full Text]
  52. Abramson, J., and Pecht, I. (2002) Immunol. Lett. 82, 23–28[CrossRef][Medline] [Order article via Infotrieve]
  53. Chacko, G. W., Tridandapani, S., Damen, J. E., Liu, L., Krystal, G., and Coggeshall, K. M. (1996) J. Immunol. 157, 2234–2238[Abstract]
  54. Osborne, M. A., Zenner, G., Lubinus, M., Zhang, X., Songyang, Z., Cantley, L. C., Majerus, P., Burn, P., and Kochan, J. P. (1996) J. Biol. Chem. 271, 29271–29278[Abstract/Free Full Text]
  55. Kimura, T., Sakamoto, H., Appella, E., and Siraganian, R. P. (1997) J. Biol. Chem. 272, 13991–13996[Abstract/Free Full Text]
  56. Vonakis, B. M., Gibbons, S., Jr., Sora, R., Langdon, J. M., and MacDonald, S. M. (2001) J. Allergy Clin. Immunol. 108, 822–831[CrossRef][Medline] [Order article via Infotrieve]
  57. Dustin, L. B., Plas, D. R., Wong, J., Hu, Y. T., Soto, C., Chan, A. C., and Thomas, M. L. (1999) J. Immunol. 162, 2717–2724[Abstract/Free Full Text]
  58. Lesourne, R., Bruhns, P., Fridman, W. H., and Daeron, M. (2001) J. Biol. Chem. 276, 6327–6336[Abstract/Free Full Text]
  59. Fong, D. C., Brauweiler, A., Minskoff, S. A., Bruhns, P., Tamir, I., Mellman, I., Daeron, M., and Cambier, J. C. (2000) J. Immunol. 165, 4453–4462[Abstract/Free Full Text]
  60. Krystal, G. (2000) Semin. Immunol. 12, 397–403[CrossRef][Medline] [Order article via Infotrieve]
  61. Schwartz, L. B., Austen, K. F., and Wasserman, S. I. (1979) J. Immunol. 123, 1445–1450[Abstract/Free Full Text]
  62. Anderson, C. C., and Sinclair, N. R. (1998) Crit. Rev. Immunol. 18, 525–544[Medline] [Order article via Infotrieve]
  63. Fleming, T. J., Donnadieu, E., Song, C. H., Laethem, F. V., Galli, S. J., and Kinet, J. P. (1997) J. Exp. Med. 186, 1307–1314[Abstract/Free Full Text]
  64. Zhang, K., Kepley, C. L., Terada, T., Daocheng, Z., Perez, H., and Saxon, A. (2004) J. Allergy Clin. Immunol., in press

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Li, A. Gustchina, J. Alexandratos, A. Wlodawer, S. Wunschmann, C. L. Kepley, M. D. Chapman, and A. Pomes
Crystal Structure of a Dimerized Cockroach Allergen Bla g 2 Complexed with a Monoclonal Antibody
J. Biol. Chem., August 15, 2008; 283(33): 22806 - 22814.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. Bachelet, A. Munitz, B. Berent-Maoz, D. Mankuta, and F. Levi-Schaffer
Suppression of Normal and Malignant Kit Signaling by a Bispecific Antibody Linking Kit with CD300a
J. Immunol., May 1, 2008; 180(9): 6064 - 6069.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Hiragun, Z. Peng, and M. A. Beaven
Cutting Edge: Dexamethasone Negatively Regulates Syk in Mast Cells by Up-Regulating Src-Like Adaptor Protein
J. Immunol., August 15, 2006; 177(4): 2047 - 2050.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. Bachelet, A. Munitz, A. Moretta, L. Moretta, and F. Levi-Schaffer
The Inhibitory Receptor IRp60 (CD300a) Is Expressed and Functional on Human Mast Cells
J. Immunol., December 15, 2005; 175(12): 7989 - 7995.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. Boulay, J.-G. Nemorin, and P. Duplay
Phosphotyrosine Binding-Mediated Oligomerization of Downstream of Tyrosine Kinase (Dok)-1 and Dok-2 Is Involved in CD2-Induced Dok Phosphorylation
J. Immunol., October 1, 2005; 175(7): 4483 - 4489.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Gomez, C. D. Ramirez, J. Rivera, M. Patel, F. Norozian, H. V. Wright, M. V. Kashyap, B. O. Barnstein, K. Fischer-Stenger, L. B. Schwartz, et al.
TGF-{beta}1 Inhibits Mast Cell Fc{epsilon}RI Expression
J. Immunol., May 15, 2005; 174(10): 5987 - 5993.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Hiragun, Z. Peng, and M. A. Beaven
Dexamethasone Up-Regulates the Inhibitory Adaptor Protein Dok-1 and Suppresses Downstream Activation of the Mitogen-Activated Protein Kinase Pathway in Antigen-Stimulated RBL-2H3 Mast Cells
Mol. Pharmacol., March 1, 2005; 67(3): 598 - 603.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/34/35139    most recent
M404318200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kepley, C. L.
Right arrow Articles by Saxon, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kepley, C. L.
Right arrow Articles by Saxon, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement